ASX RELEASE.

12 February 2026

EMYRIA EXPANDS INVESTOR ACCESS INTO EUROPE

Emyria securities to be traded via Frankfurt Quotation Board (Open Market) broadening investor reach following multi-site clinical expansion and reimbursement foundations.

- **European investor engagement program launched** to broaden international shareholder participation and increase visibility across key European capital markets.
- **EMD securities can be traded in Europe on the Frankfurt Open Market** - ticker (FSE:Q84).
- **Frankfurt stock exchange is second largest in Europe** and provides European institutional and specialist investors with local market access, enhanced visibility, and an additional participation pathway alongside the Company's ASX listing.
- **Initiative aligns with growing European institutional focus on innovative mental health services** that are evidence-based and reimbursed, including next-generation therapies for conditions such as depression and PTSD.
- **Specialist European IR advisor appointed -** Dr Reuter Investor Relations engaged to support European investor engagement, with a focus on the DACH region (Germany, Austria and Switzerland).
- **European engagement follows a period of accelerating operational growth** supported by delivering long-term durable clinical outcomes, strong quarterly revenue growth, a multi-state Empax clinic footprint and dual reimbursement pathways with both private insurers and government payers.

Emyria Limited (ASX: EMD) ("Emyria", or the "Company") a leader in developing and delivering innovative mental health treatments, has commenced a structured European investor engagement program to expand international shareholder participation and awareness of the Company's integrated, reimbursement-backed mental health clinical model.

Strategic Rationale for European Engagement

Europe represents one of the most active global regions for healthcare innovation, institutional capital allocation and reimbursement-driven service models, particularly within mental health and neuroscience. Across the region, institutional and specialist investors are increasingly focused on scalable, evidence-based treatment platforms supported by clinical validation, regulatory engagement and established healthcare infrastructure.

A Frankfurt *Open Market* presence is anticipated to improve European institutional access by providing local market visibility and participation pathways, facilitate valuation benchmarking against global mental health peers, and support long-term liquidity alongside the Company's ASX listing.

Notably, being on the Frankfurt Open Market does not impose any additional compliance or regulatory requirements for the company, nor does it have any ongoing administrative costs.

Executive Chairman of Emyria, Greg Hutchinson, said:
"Emyria has reached a stage in its development where our national clinic footprint, accelerating revenue growth, dual reimbursement pathways and durable real-world PTSD outcomes position us for broader international engagement.

Commencing structured European investor outreach is a logical extension of our strategy to improve accessibility for institutional and specialist healthcare investors, while our operational focus remains firmly on what has brought us to this point. That is, clinical execution, durable patient outcomes, disciplined expansion and the continued broadening of reimbursement pathways."

European Investor Relations Support
To support its European engagement activities, Emyria has engaged Dr Reuter Investor Relations, a specialist European investor relations firm with extensive experience assisting ASX-listed life-sciences and healthcare companies in building long-term investor awareness and participation across European capital markets, particularly within the DACH region.

Dr Eva Reuter, CEO of Dr Reuter Investor Relations, commented:
"Emyria joining the Frankfurt Open Market comes at a time of accelerating European institutional and specialist interest in next-generation mental health therapies. Across Europe, investor attention is increasingly aligned with clinical momentum in areas such as psychedelic-assisted approaches for depression and PTSD—supported by active clinical programs in the region, including the European arm of COMPASS Pathways' Phase 3 psilocybin program in treatment-resistant depression and European MDMA-assisted psychotherapy studies. It also places Emyria alongside sector peers that already trade on the Frankfurt Open Market."

This release has been approved by the Board of Emyria.

Greg Hutchinson | Executive Chair
1300 436 363 | investors@emyria.com

Emyria Limited develops and delivers new treatments for mental health and select neurological conditions through an integrated model of direct clinical services and treatment development:



Emyria Healthcare: Evidence-based treatment for patients not finding relief from conventional care while also helping evaluate emerging new therapies like assisted therapy for PTSD and assisted therapy for treatment-resistant depression.

Emyria Data: Robust and ethically sourced Real-World Data gathered with patients to improve Emyria's unique therapy and drug development programs.

Emyria's Pipeline: New psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases.

EMYRIA'S INTERACTIVE INVESTOR HUB

Investorhub.emyria.com Interact with Emyria's announcements and updates by asking questions and comments, which our team can respond to where possible.

CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

Risks associated with the use of MDMA, MDMA-inspired compounds and psilocybin

All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding. Adverse effects of MDMA include high blood pressure, increased pulse rate, faintness, and panic attacks, and in some rare cases it can cause loss of consciousness or trigger seizures. Other side effects include involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating and muscle/joint stiffness. Adverse effects of psilocybin can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. The effects of MDMA and psilocybin are unlikely at low doses in the treatment regimens used in psychedelic-assisted psychotherapy while appropriately managed in a controlled environment with direct medical supervision. The risk profile of the MDMA inspired compounds is currently unknown.

The availability of these products is subject to the safety and efficacy of the products being tested through clinical trials. Emyria makes no representations or warranties as to the safety or efficacy of the products or the products' ability (or the ability of its key compounds) to be used in the treatment of indications such as PTSD. There are currently no approved products containing MDMA, psilocybin or MDMA inspired compounds that the TGA has evaluated for quality, safety and efficacy.